CITR Annual
Report Report
Exhibits
CITR
Annual
Exhibits
Prepared by:
CITR Coordinating Center
The EMMES Corporation
Rockville, MD
Sponsored by:
National Institute of Diabetes & Digestive & Kidney Diseases
National Institutes of Health
Bethesda, MD
Datafile Closure: April 3, 2006
Table of Contents
Section 1: Registry Summary
Section 2: Islet Transplant Alone Information
Chapter 1: Participant and Donor Characteristics
Chapter 2: Pancreas Procurement and Islet Processing
Chapter 3: Immunosuppressive and Other Medications
Chapter 4: Graft Function
Chapter 5: Recipient’s Laboratory Data
Chapter 6: Adverse Events
Section 3: Islet After Kidney Transplant Information
Section 4: Registry Data Quality Review
CITR Coordinating Center
CITR Committees
Section 1: Registry Summary
Contributing Islet Transplant Centers (N=23)
Number of Islet Transplant Programs Transplanting and
Number Reporting Information to CITR by Year
Total Number of Recipients Receiving Their First Islet
Allograft Infusion in North America as Reported to the
Registry and Number Contained in the Annual Report
The Islet Transplant Summary (ITS) questionnaire is completed by all North American Islet Transplant
Programs regardless of their participation in the Registry. Of 42 North American islet transplant programs
polled, all have provided this information through 2005.
Total Number of Islet Allograft Infusion Procedures
Performed in North America as Reported to the Registry
and Number Contained in the Annual Report
The Islet Transplant Summary (ITS) questionnaire is completed by all North American islet transplant
programs regardless of their participation in the Registry. Of 42 North American islet transplant programs
polled, all have provided this information through 2005.
Total Number of Islet Allograft Infusion Procedures
Conducted and Entered in CITR Database by Year and by
Infusion Procedure Number (All Participants, N=225)
Total Number of Islet Allograft Infusion Procedures
Received Per Participant (All Participants, N=225)
Summary of Transplant Types
(All Participants, N=227)
Section 2: Islet Transplant Alone Information
Chapter 1: Participant and Donor
Characteristics
Participant Demographics
Participant Summary Measures at First Infusion
Participant Characteristics
Participant’s Primary Payer and Employment
Status at Time of First Infusion
Participant Status at First Infusion
Participant Status at First Infusion (continued)
Participant Serology at Screening
Participant Baseline Demographics Prior to First Infusion
by Total Number of Infusions Received
Participant Demographics Prior to First Infusion by Total
Number of Infusions Received
Infusion Summary by Infusion Sequence
Infusion Summary by Infusion Sequence (continued)
Pre Infusion Portal Pressure (mmHg) by Infusion Sequence
Peak Portal Pressure (mmHg) by Infusion Sequence
Closure Portal Pressure (mmHg) by Infusion Sequence
Change from Pre Infusion to Closure Portal Pressure (mmHg)
by Infusion Sequence
Change from Pre Infusion to Peak Portal Pressure (mmHg) by
Infusion Sequence
Packed Cell Volume (mL) Used During Infusion
by Infusion Year
Donor Characteristics
Donor Characteristics and Hospitalization
Summary Information
Donor Characteristics and Hospitalization
Summary Information (continued)
Donor Characteristics and Hospitalization
Summary Information (continued)
Donor Characteristics and Hospitalization
Summary Information (continued)
Donor Age (yrs)
Donor Weight (kg)
Donor Body Mass Index (kg/m2)
Time from Cross Clamp to
Pancreas Recovery (mins)
Donor Characteristics: Use of Vasopressors
Donor Serology
Donor Laboratory Data
Donor Serum Creatinine (mg/dL)
Donor BUN (mg/dL)
Donor Total Bilirubin (mg/dL)
Donor AST (IU/L)
Donor ALT (IU/L)
Donor Serum Lipase (IU/L)
Donor Serum Amylase (IU/L)
Donor Pre-Insulin Blood Glucose (mg/dL)
Donor Maximum Blood Glucose (mg/dL)
Chapter 2: Pancreas Procurement and
Islet Processing
Islet Processing Summary
Islet Processing Summary (continued)
Cold Ischemia Information
Summary of Islet Equivalents and Timing of Count
Islet Product Characterization
Total Islet Equivalents by Cold Ischemic Time (hrs)
All Pancreas Preservation Methods
Total Islet Equivalents by Cold Ischemic Time (hrs)
Pancreata Preserved with UW Only
Total Islet Equivalents by Cold Ischemic Time (hrs)
Pancreata Preserved with Two Layer Only
Total Islet Equivalents by Donor Body Mass Index (kg/m2)
Total Islet Equivalents by Donor Age (yrs)
Islet Characteristics by Time from Cross
Clamp to Pancreas Recovery
Islet Characteristics by Pancreas Preservation Method
Islet Characteristics by Cold Ischemic Time (hrs)
Islet Characteristics by Islet Pretreatment Method
Islet Characteristics by Donor Age (hrs)
Islet Characteristics by Donor Body Mass Index (kg/m2)
Mean Number of Islet Equivalents/kg Participant ( SD)
by Total Number of Infusions Received
(Recipients with a Total of 1 Infusion, 2 Infusions, and 3 Infusions)
Chapter 3: Immunosuppressive and
Other Medications
Immunosuppression Regimen at Time of First Infusion
Summary of T Cell Antibodies Used During First
Infusion for Induction Therapy
Immunosuppression Dosing (mg/day) at Time of
Infusion by Infusion Sequence
Induction Therapy at Time of Infusion
by Infusion Sequence
Immunosuppression Therapy Use Post Last Infusion
Immunosuppression Dosing Post Last Infusion
Sirolimus Trough Level (ng/mL) Post Last Infusion
Tacrolimus Trough (ng/mL) Level Post Last Infusion
Use of Anti-Hypertensive Medications at
Pre Infusion and Post Last Infusion
Percent of Participants Using Anti-Hypertensive
Medications at Pre Infusion and Post Last Infusion
Use of Lipid Lowering Medications Pre Infusion
and Post Last Infusion
Percent of Participants Using Lipid Lowering Medications at
Pre Infusion and Post Last Infusion
Adjunctive Therapy Used at Time of First Infusion
Adjunctive Therapy Used During Follow-Up
Post Last Infusion
Adjunctive Therapy Used During Follow-Up
Post Last Infusion (continued)
Chapter 4: Graft Function
Participant’s Insulin Status at Follow-up
Post First and Last Infusion
Participant’s Insulin Status at Follow-Up Post Last Infusion
by Total Number of Infusions Received
Percent of Participants Ever Achieving Insulin Independence
Percent of Participants Ever Achieving Insulin Independence
by the Infusion Received When Insulin Independence
was Achieved
Time to Return to Insulin Dependence
( 14 Days of Insulin Use)
Among Insulin Independent Participants
Time to Return to Insulin Dependence (  14 Days of Insulin Use)
Stratified by Total Number of Infusions Needed to First Achieve
Insulin Independence
Among Insulin Independent Participants
Percent of Participants by Outcome Level at Follow-Up
Post Last Infusion
Insulin Status (%) by Follow-Up Visit Post Last Infusion
Percent of Insulin Independent Participants
Post Last Infusion
Percent of Insulin Independent Participants Post Last
Infusion by Total Number of Infusions Received
Reduction of Insulin (%) From Baseline to Follow-Up
Post Last Infusion
Participants on Insulin
Average Daily Insulin Use (Units) at
Follow-Up Post Last Infusion
Participants on Insulin
Percentage of Baseline Insulin Use at Follow-Up
Post Last Infusion
Recipients Ever Achieving Insulin Independence
Percentage of Baseline Insulin Use at Follow-Up
Post Last Infusion
Recipients Never Achieving Insulin Independence
Average Daily Insulin Use (Units/kg) at Baseline and
Post Last Infusion
Participants on Insulin
Insulin Independence (%) Year 1 Post First Infusion by
Participant’s Weight (kg) at Baseline
Insulin Independence (%) Year 1 Post First Infusion by
Participant’s Average Daily Insulin Use (Units/Day)
at Baseline
Insulin Independence at Month 6 and Year 1 Post Last
Infusion by Donor and Participant Characteristics
Insulin Independence at Month 6 and Year 1 Post Last
Infusion by Donor and Participant Characteristics (continued)
Basal C-Peptide  0.5 ng/mL at Month 6 and Year 1
Post Last Infusion
by Donor and Participant Characteristics
Basal C-Peptide  0.5 ng/mL at Month 6 and Year 1
Post Last Infusion
by Donor and Participant Characteristics (continued)
HbA1C  6.5% at Month 6 and Year 1 Post Last Infusion
by Donor and Participant Characteristics
HbA1C  6.5% at Month 6 and Year 1 Post Last Infusion
by Donor and Participant Characteristics (continued)
Outcome Levels at Month 6 Post Last Infusion
by Donor and Participant Characteristics
Outcome Levels at Month 6 Post Last Infusion by
Donor and Participant Characteristics (continued)
Outcome Levels at Year 1 Post Last Infusion by
Donor and Participant Characteristics
Outcome Levels at Year 1 Post Last Infusion by
Donor and Participant Characteristics (continued)
Participant Outcome at Month 6 Post Last Infusion by
Mean Donor Age Over All Infusions (yrs)
Participant Outcome at Year 1 Post Last Infusion by
Mean Donor Age Over All Infusions (yrs)
Participant Outcome at Month 6 Post Last Infusion by
Participant Age at Baseline (yrs)
Participant Outcome at Year 1 Post Last Infusion by
Participant Age at Baseline (yrs)
Participant Outcome at Month 6 Post Last Infusion by
Duration of Diabetes at Baseline (yrs)
Participant Outcome at Year 1 Post Last Infusion by
Duration of Diabetes at Baseline (yrs)
Participant Outcome at Month 6 Post Last Infusion by
Participant Body Mass Index (kg/m2)
Participant Outcome at Year 1 Post Last Infusion by
Participant Body Mass Index (kg/m2)
Participant Outcome at Month 6 Post Last Infusion by
Insulin Use (Units/kg Participant Weight at Baseline)
Participant Outcome at Year 1 Post Last Infusion by
Insulin Use (Units/kg Participant Weight at Baseline)
Participant Outcome at Month 6 Post Last Infusion by
Participant Gender
Participant Outcome at Year 1 Post Last Infusion by
Participant Gender
Participant Outcome at Month 6 Post Last Infusion by
Any Elevated Liver Function Tests Prior to Assessment
Participant Outcome at Year 1 Post Last Infusion by
Any Elevated Liver Function Tests Prior to Assessment
Participant Outcome at Month 6 Post Last Infusion by
Any Adverse Event Related to Infusion Prior to Assessment
Participant Outcome at Year 1 Post Last Infusion by
Any Adverse Event Related to Infusion Prior to Assessment
Participant Outcome at Month 6 Post Last Infusion by
Mean Donor Body Mass Index (kg/m2)
Participant Outcome at Year 1 Post Last Infusion by
Mean Donor Body Mass Index (kg/m2)
Participant Outcome at Month 6 Post Last Infusion by
Islet Equivalents/kg Participant Weight
Participant Outcome at Year 1 Post Last Infusion by
Islet Equivalents/kg Participant Weight
Summary of Severe Hypoglycemic Events Pre First
Infusion and Follow-Up Post Last Infusion
Percent of Participants with One or More Occurrences of
Severe Hypoglycemic Episodes Pre First Infusion and
Follow-Up Post Last Infusion
Insulin Independence by Immunosuppression Regimen
Insulin Independence at Month 6 by Immunosuppression
Regimen All Participants on Sirolimus, Tacrolimus, and
Daclizumab at Baseline
Insulin Independence at Year 1 by Immunosuppression
Regimen All Participants on Sirolimus, Tacrolimus, and
Daclizumab at Baseline
Insulin Status at Post Last Infusion Follow-Up and
Sirolimus Trough Level (ng/mL)
Insulin Status at Post Last Infusion Follow-Up and Tacrolimus
Trough Level (ng/mL)
Fasting Plasma Glucose (mg/dL) Pre Infusion
and Post Last Infusion
HbA1C (%) Pre Infusion and Post Last Infusion
Basal Plasma C-Peptide (ng/mL) Pre Infusion
and Post Last Infusion
Fasting Plasma Glucose (mg/dL) Pre Infusion
and Post Last Infusion
Participants with One Infusion
HbA1C (%) Pre Infusion and Post Last Infusion
Participants with One Infusion
Basal Plasma C-peptide (ng/mL) Pre Infusion
and Post Last Infusion
Participants with One Infusion
Fasting Plasma Glucose (mg/dL) Pre Infusion
and Post Last Infusion
Participants with Two Infusions
HbA1C (%) Pre Infusion and Post Last Infusion
Participants with Two Infusions
Basal Plasma C-peptide (ng/mL) Pre Infusion
and Post Last Infusion
Participants with Two Infusions
Fasting Plasma Glucose (mg/dL) Pre Infusion
and Post Last Infusion
Participants with Three Infusions
HbA1C (%) Pre Infusion and Post Last Infusion
Participants with Three Infusions
Basal Plasma C-peptide (ng/mL) Pre Infusion
and Post Last Infusion
Participants with Three Infusions
Fasting Plasma Glucose (mg/dL) Post Last Infusion
Participants Who Ever Achieved Insulin Independence
Fasting Plasma Glucose (mg/dL) Post Last Infusion
Participants Who Never Achieved Insulin Independence
HbA1C (%) Post Last Infusion Participants Who Ever
Achieved Insulin Independence
HbA1C (%) Post Last Infusion Participants Who Never
Achieved Insulin Independence
Basal Plasma C-Peptide (ng/mL) Post Last Infusion
Participants Who Ever Achieved Insulin Independence
Basal Plasma C-Peptide (ng/mL) Post Last Infusion
Participants Who Never Achieved Insulin Independence
Fasting Plasma Glucose (mg/dL) Pre and Post First Infusion
Insulin Independent Participants
Fasting Plasma Glucose (mg/dL) Pre and Post First Infusion
Insulin Dependent Participants
HbA1C (%) Pre and Post First Infusion
Insulin Independent Participants
HbA1C (%) Pre and Post First Infusion
Insulin Dependent Participants
Basal Plasma C-peptide (ng/mL) Pre and Post First Infusion
Insulin Independent Participants
Basal Plasma C-peptide (ng/mL) Pre and Post First Infusion
Insulin Dependent Participants
Participants with Fasting Blood Glucose < 126 mg/dL
Post Last Infusion
All Participants
Participants with Basal C-Peptide  0.5 ng/mL
Post Last Infusion
All Participants
Participants with HbA1C  6.5 %
Post Last Infusion
All Participants
Pre Infusion Recipient Lab Summary
by Infusion Sequence
Metabolic Summary by Follow-Up
Post Last Infusion
Metabolic Summary Month 6 Post Last Infusion
by Insulin Status
Metabolic Summary Year 1 Post Last Infusion
by Insulin Status
Change in Islet Graft Function and Recipient Survival
Summary Post Last Infusion
*One recipient died 70 days following their third islet cell infusion. The cause of death for this recipient was reported as
acute methadone and diphenhydramine toxicity unrelated to both the infusion procedure and immunosuppression therapy.
An additional recipient death has been reported which occurred after Year 3 post last infusion. The cause of death for this
recipient was reported as viral meningitis possibly related to the immunosuppression therapy. Finally, a third death was
reported which occurred after Year 4 post last infusion. The death was discovered in the obituaries and the cause of death
is unknown.
Change in Islet Graft Function Summary
Change in Islet Graft Function Summary (continued)
Change in Islet Graft Function Summary (continued)
Time to Complete Islet Graft Failure
All Participants from Centers Reporting Islet Graft Failures
Summary of Secondary Complications Pre First
Infusion and Post Last Infusion
Summary of Secondary Complications Pre First
Infusion and Post Last Infusion (continued)
Summary of Secondary Complications Pre First
Infusion and Post Last Infusion (continued)
Summary of Ocular Complications
Post Last Infusion
Chapter 5: Recipient’s Laboratory Data
Participants with Abnormal Liver Function
Tests Post Infusion
Participants with Abnormal Liver Function
Tests Post Infusion (continued)
ALT (IU/L) Pre Infusion and Post Last Infusion
AST (IU/L) Pre Infusion and Post Last Infusion
Alkaline Phosphatase (IU/L) Pre Infusion
and Post Last Infusion
Total Bilirubin (mg/dL) Pre Infusion
and Post Last Infusion
Participants with Abnormal Lipid Tests
Post First Infusion
Participants with Abnormal Lipid Tests
Post First Infusion (continued)
Total Cholesterol (mg/dL) Pre Infusion
and Post Last Infusion
HDL (mg/dL) Pre Infusion and Post Last Infusion
LDL (mg/dL) Pre Infusion and Post Last Infusion
Triglycerides (mg/dL) Pre Infusion
and Post Last Infusion
Percent of Participants with an Increase in Serum
Creatinine (mg/dL) Greater than 0.5 from Baseline
Serum Creatinine (mg/dL) Pre Infusion
and Post Last Infusion
Calculated Creatinine Clearance (mL/min/1.73m2)
Pre Infusion and Post Last Infusion
Chapter 6: Adverse Events
Summary of Adverse Events and Serious Adverse Events
(SAEs) in Year 1 Post First Infusion (Participants, N=203)
Percent of Participants with a Serious Adverse Event in Year
1 Post First Infusion by Year of Infusion
Summary of All Serious Adverse Events (SAEs)
Reported by Type of SAE
Summary of All Serious Adverse Events (SAEs)
Reported and their Outcome
Summary of All Serious Adverse Events (SAEs)
Reported by System Organ Class
Summary of All Serious Adverse Events (SAEs)
Reported by System Organ Class (continued)
Most Common Serious Adverse Events (SAEs),
Reported for All Participants (Total SAEs, N=236)
All Serious Adverse Events (SAEs)
Reported in Alphabetical Order
All Serious Adverse Events (SAEs)
Reported in Alphabetical Order (continued)
All Serious Adverse Events (SAEs)
Reported in Alphabetical Order (continued)
All Serious Adverse Events (SAEs)
Reported in Alphabetical Order (continued)
All Serious Adverse Events (SAEs)
Reported in Alphabetical Order (continued)
All Serious Adverse Events (SAEs)
Reported in Alphabetical Order (continued)
All Serious Adverse Events (SAEs)
Reported in Alphabetical Order (continued)
All Serious Adverse Events (SAEs)
Reported in Alphabetical Order (continued)
All Serious Adverse Events (SAEs)
Reported in Alphabetical Order (continued)
All Serious Adverse Events (SAEs)
Reported in Alphabetical Order (continued)
All Serious Adverse Events (SAEs)
Reported in Alphabetical Order (continued)
All Serious Adverse Events (SAEs)
Reported in Alphabetical Order (continued)
All Serious Adverse Events (SAEs)
Reported in Alphabetical Order (continued)
All Serious Adverse Events (SAEs)
Reported in Alphabetical Order (continued)
All Serious Adverse Events (SAEs)
Reported in Alphabetical Order (continued)
All Serious Adverse Events (SAEs)
Reported in Alphabetical Order (continued)
All Serious Adverse Events (SAEs)
Reported in Alphabetical Order (continued)
All Serious Adverse Events (SAEs)
Reported in Alphabetical Order (continued)
All Serious Adverse Events (SAEs)
Reported in Alphabetical Order (continued)
All Serious Adverse Events (SAEs)
Reported in Alphabetical Order (continued)
All Serious Adverse Events (SAEs)
Reported in Alphabetical Order (continued)
All Serious Adverse Events (SAEs)
Reported in Alphabetical Order (continued)
Summary of Reported Neoplasms
(benign, malignant, unspecified) All Participants
Number of Days Hospitalized at Infusion
(Admission to Discharge) by Infusion Sequence
Hospitalizations Experienced Post Last Infusion
by Total Number of Infusions Received
Section 3: Islet After Kidney Transplant
Information
Participant Demographics
Participant Characteristics
Participant’s Primary Payer and Employment Status
at Time of First Infusion
Participant Status at First Infusion
Participant Status at First Infusion (continued)
Participant Summary Measures at First Infusion
Participant Serology at Screening
Infusion Summary by Infusion Sequence
Donor Characteristics
Donor Characteristics and Hospitalization
Summary Information
Donor Characteristics and Hospitalization
Summary Information (continued)
Donor Characteristics and Hospitalization
Summary Information (continued)
Donor Characteristics and Hospitalization
Summary Information (continued)
Donor Characteristics: Use of Vassopressors
Donor Serology
Donor Laboratory Data
Islet Processing Summary
Islet Processing Summary (continued)
Cold Ischemia Information
Summary of Islet Equivalents and Timing of Count
Islet Product Characterization
Mean Number of Islet Equivalents/kg (SD)
by Total Number of Infusions Received
Immunosuppression Regimen at Time of First Infusion
Immunosuppression Dosing (mg/day) at Time of
Infusion by Infusion Sequence
Induction Therapy (mg) at Time of Infusion
by Infusion Sequence
Immunosuppression Therapy Use Post Last Infusion
Immunosuppressive Dosing Post Last Infusion
Sirolimus Trough Level (ng/mL) Post Last Infusion
Tacrolimus Trough Level (ng/mL) Post Last Infusion
Participant’s Insulin Status at Follow-Up Post First
and Last Infusion
Reduction in Insulin (%) from Pre Infusion to Follow-Up
Post Last Infusion Participants on Insulin
Summary of Severe Hypoglycemic Events
by Pre First Infusion and Follow-Up Post Last Infusion
Fasting Plasma Glucose (mg/dL) Pre Infusion
and Post Last Infusion
HbA1C (%) Pre Infusion and Post Last Infusion
Basal Plasma C-peptide (ng/mL) Pre Infusion
and Post Last Infusion
Pre Infusion Recipient Lab Summary
by Infusion Sequence
Participants with Abnormal Liver Function Tests
Post Infusion
Participants with Abnormal Liver Function Tests
Post Infusion (continued)
ALT (IU/L) Pre Infusion and Post Last Infusion
AST (IU/L) Pre Infusion and Post Last Infusion
Alkaline Phosphatase (IU/L) Pre Infusion
and Post Last Infusion
Total Bilirubin (mg/dL) Pre Infusion and Post Last Infusion
Participants with Abnormal Lipid Tests Post Infusion
Participants with Abnormal Lipid Tests
Post Infusion (continued)
Total Cholesterol (mg/dL) Pre Infusion
and Post Last Infusion
HDL (mg/dL) Pre Infusion and Post Last Infusion
LDL (mg/dL) Pre Infusion and Post Last Infusion
Triglycerides (mg/dL) Pre Infusion and Post Last Infusion
Percent of Participants with an Increase in Serum
Creatinine (mg/dL) Greater than 0.5 from Baseline
Serum Creatinine (mg/dL) Pre Infusion
and Post Last Infusion
Calculated Creatinine Clearance (mL/min/1.73m2)
Pre Infusion and Post Last Infusion
Summary of Adverse Events and Serious Adverse Events
in Year 1 Post First Infusion (Participants, N=22)
Summary of All Serious Adverse Events (SAEs)
by Type of SAE
Summary of All Serious Adverse Events (SAEs)
Reported and their Outcome
Summary of All Serious Adverse Events (SAEs)
by System Organ Class
Summary of All Serious Adverse Events (SAEs)
by System Organ Class (continued)
All Serious Adverse Events (SAEs) Reported
in Alphabetical Order
All Serious Adverse Events (SAEs) Reported
in Alphabetical Order (continued)
All Serious Adverse Events (SAEs) Reported
in Alphabetical Order (continued)
All Serious Adverse Events (SAEs) Reported
in Alphabetical Order (continued)
Number of Days Hospitalized at Infusion
(Admission to Discharge) by Infusion Sequence
Hospitalizations Experienced Post Last Infusion
by Total Number of Infusions Received
Changes in Portal Pressure (mmHg) and Infusion Summary
by Infusion Sequence
Changes in Portal Pressure (mmHg) and Infusion Summary
by Infusion Sequence (continued)
Section 4: Registry Data Quality
Review
Expected and Submitted Forms by Infusion Sequence
(All Participants, N=227)
Expected and Submitted Follow-Up Forms
Post Last Infusion
Extent of Follow-Up Post Last Infusion
(All Participants, N=227)
Summary of All Participants Reported as Lost to
CITR Follow-Up
CITR Coordinating Center
(July 2005 – July 2006)
PI: Nicole Close
Co-PI: Donald Stablein
Bryan Calaway
James Cravens
Yong Lin
Jessica Long
Glenn Tucker
Chuck Wagner
Steve Wease
CITR Committees
Scientific Advisory Committee (SAC)
Compliance Committee
Data Monitoring Committee
Publications/Presentations Committee
Transplant Coordinators’/Data Managers’ Committee
CITR Scientific Advisory Committee (SAC)
Chair: Bernhard J. Hering
Reinhard G. Bretzel
Michael Cecka
Mary D. Ellison
Olle Korsgren
Jerry P. Palmer
Camillo Ricordi
A.M. James Shapiro
CITR Compliance Committee
Michael Appel
E. Brian Flanagan
Fouad Kandeel
Eileen M. Markmann
David Radosevich
Marti Sears
Elyse Stuart
CITR Data Monitoring Committee
Chair: Marc Garfinkel
David Baidal
Enrico Cagliero
Fouad Kandeel
Dixon Kaufman
Jeff Longmate
Melissa Roberts
Marti Sears
CITR Publications/Presentations Committee
Chair: Rodolfo Alejandro
Michael Appel
Nancy Bridges
Elizabeth Holbrook
Ali Naji
A.M. James Shapiro
Craig Smith
CITR Transplant Coordinators’/
Data Managers’ Committee
Chair: Marti Sears
Debra Kemp
Grace Sauzier
David Baidal
Carol Kramer
Jill Sheedy
Terri Baker
Kathleen LaBranche
KD Shiang
Susan Comninel
Linda Langman
Paige Schock
Barbara Culbreath
Arlene LaRose
Winsor Simmons
Arthur Dea
Lorraine Lesiecki
Elyse Stuart
Parastoo Dinyari
Eileen Markmann
Pat Swanson
Cheryl Durkop
Marli McCulloch-Olson
Heather Turgeon
Debbie Grice
Deborah McGhee-Wilson
Terri Wakefield
Darrell Grimes
Lori Otken
Kimber Westbrook
Jeannette Hacker
Maral Palanjian
Deana Williams
Celia Hartigan
Jamen Parkey
Piotr Witkowski
Elizabeth Holbrook
Melissa Roberts
Elizabeth Wright
Robin Jevne
Donna Sarman
Tiffany Zgabay